Results 251 to 260 of about 22,239 (295)

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

Xenobiotica, 2013
1. The absorption, metabolism and excretion of teneligliptin were investigated in healthy male subjects after a single oral dose of 20 mg [(14)C]teneligliptin. 2. Total plasma radioactivity reached the peak concentration at 1.33 h after administration and thereafter disappeared in a biphasic manner.
Yoshinobu, Nakamaru, Yoshiharu, Hayashi, Ruriko, Ikegawa, Shuji, Kinoshita, Begonya, Perez Madera, Dave, Gunput, Atsuhiro, Kawaguchi, Martin, Davies, Stuart, Mair, Hiroshi, Yamazaki, Toshiyuki, Kume, Masayuki, Suzuki   +11 more
openaire   +2 more sources

Dipeptidyl Peptidase-IV Inhibitors for Diabetes Mellitus

Journal of Research in Medical Education & Ethics, 2012
Dipeptidyl peptidase (DPP) IV inhibitors are drugs which prolong the action of Glucagon like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP). The DPP IV inhibitors have shown improved glycemic control, and reduction of glycosylated haemoglobin in patients with type-2 diabetes.
Prithpal S Matreja, Jaspreet Kaur, Ashwani K Gupta, Amandeep Singh, P M L Khanna, H P Kayath   +5 more
openaire   +1 more source

Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in the Inpatient Setting

Journal of Pharmacy Practice, 2020
Background: The American Diabetes Association recommends discontinuing non-insulin antihyperglycemic therapy during hospitalization and utilizing a basal insulin-containing regimen for patients with type 2 diabetes mellitus (T2DM). Limited research is available on the role of dipeptidyl peptidase-IV (DPP-IV) inhibitors in an inpatient real-world ...
Sarah E. Petite, Maja C. Hill
openaire   +2 more sources

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2007
The synthesis and structure-activity relationships of novel dipeptidyl peptidase IV inhibitors replacing the classical cyanopyrrolidine P1 group with other small nitrogen heterocycles are described. A unique potency enhancement was achieved with beta-branched natural and unnatural amino acids, particularly adamantylglycines, linked to a (2S,3R)-2,3 ...
Ligaya M, Simpkins, Scott, Bolton, Zulan, Pi, James C, Sutton, Chet, Kwon, Guohua, Zhao, David R, Magnin, David J, Augeri, Timur, Gungor, David P, Rotella, Zhong, Sun, Yajun, Liu, William S, Slusarchyk, Jovita, Marcinkeviciene, James G, Robertson, Aiying, Wang, Jeffrey A, Robl, Karnail S, Atwal, Robert L, Zahler, Rex A, Parker, Mark S, Kirby, Lawrence G, Hamann   +21 more
openaire   +2 more sources

Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2005
The sole application of an inhibitor of the dipeptidyl peptidase DP IV (also DP 4, CD26, DPP-IV or DPP-4) to a mammal subsequently leading to improved glucose tolerance marks a major breakthrough in metabolic research bearing the potential of a new revolutionary diabetes therapy.
Hans-Ulrich, Demuth, Christopher H S, McIntosh, Raymond A, Pederson   +2 more
openaire   +2 more sources

GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors

2011
Novel therapeutic options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were introduced in 2005. Incretin-based therapies consist of two classes: (1) the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor and (2) dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) as oral medications ...
openaire   +2 more sources

A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors

European Journal of Medicinal Chemistry, 2008
Dipeptidyl peptidase IV (DPP-IV) is a valid drug target for type-2 diabetes and DPP-IV inhibitors have been proven to efficiently improve glucose tolerance. In our study, 3D pharmacophore models were generated using a training set of 22 DPP-IV inhibitors.
I-Lin, Lu, Keng-Chang, Tsai, Yi-Kun, Chiang, Weir-Torn, Jiaang, Ssu-Hui, Wu, Neeraj, Mahindroo, Chia-Hui, Chien, Shiow-Ju, Lee, Xin, Chen, Yu-Sheng, Chao, Su-Ying, Wu   +10 more
openaire   +2 more sources

Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views

Current Topics in Medicinal Chemistry, 2005
Prevalence of type 2 diabetes has increased dramatically in the last decades. Current medicines are not yet capable to efficiently prevent or reverse progression of the disease and its associated comorbidities. As a consequence, there is a great need for novel antidiabetic drugs.
Daniel, Hunziker, Michael, Hennig, Jens-Uwe, Peters   +2 more
openaire   +2 more sources

Dipeptidyl peptidase IV inhibitors.

IDrugs : the investigational drugs journal, 2003
The patent literature for dipeptidyl peptidase IV (DPP-IV) inhibitors for the period of January 2001 to May 2002 is reviewed. There has been increased interest in DPP-IV inhibitors since their potential for the treatment of diabetes was identified. This review will focus on reversible inhibitors of the enzyme, for which the primary interest has been ...
openaire   +1 more source

Potent and selective proline derived dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
In-house screening of the Merck sample collection identified proline derived homophenylalanine 3 as a DPP-IV inhibitor with modest potency (DPP-IV IC50=1.9 microM). Optimization of 3 led to compound 37, which is among the most potent and selective DPP-IV inhibitors discovered to date.
Scott D, Edmondson, Anthony, Mastracchio, Maria, Beconi, Lawrence F, Colwell, Bahanu, Habulihaz, Huaibing, He, Sanjeev, Kumar, Barbara, Leiting, Kathryn A, Lyons, Ann, Mao, Frank, Marsilio, Reshma A, Patel, Joseph K, Wu, Lan, Zhu, Nancy A, Thornberry, Ann E, Weber, Emma R, Parmee   +16 more
openaire   +2 more sources